echohan999

SARS-CoV-2 is a positive-sense single-stranded RNA virus, and it’s a strain of severe acute respiratory syndrome-related coronavirus (SARSr-CoV). Coronaviruses consist of four genus: α, β, γ, and δ. The coronaviruses that infect mammals are mainly α and β genus. Among the viruses capable of infecting humans, HCoV-229E and HCoV-NL63 belong to the α coronavirus, and HCoV-OC43, SARS-CoV, HCoV-HKU1, MERS-CoV, and SARS-CoV-2 belong to the β coronavirus. https://viroantibody.creative-biolabs.com/category-sars-cov-2-369.htm

For a new viral disease to emerge, the causative virus must infect and successfully invade its host, bypassing the complex and sophisticated antiviral defenses that have evolved in all animals. Three major steps have been distinguished in the processes of viral disease emergence or re-emergence: (1) introduction of a viral pathogen into a new host species, (2) establishment of the pathogen in the new host, and (3) dissemination of the pathogen among a large number of individuals of the new host species to bring about outbreaks, epidemics or pandemics. https://viroantibody.creative-biolabs.com/viruses-and-diseases.htm

Primary antibodies are immunoglobulins that bind to a specific antigen of interest, such as protein, peptide, small molecule. And, they are commonly unconjugated. A primary antibody can recognize and bind with high affinity and specificity to purify, detect, and measure the antigen. Using a variety of hosts, such as mouse, rabbit, goat, or chicken, primary antibodies are available as polyclonal or monoclonal relying on their applications. https://viroantibody.creative-biolabs.com/category-primary-antibodies-365.htm

Antibody-drug conjugates (ADCs) are innovative next-generation immune therapy agents that combine the specific targeting capacity of a monoclonal antibody with cytotoxic drugs. They are designed for accurate drug delivery to minimize collateral damages to healthy tissues. With the antibody Fc region that triggers antibody dependent cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) and the cytotoxicity of the payload drug, some ADCs exert a “two-fold” killing efficacy towards targeted cancer cells. https://www.creative-biolabs.com/adc/adc-in-vivo-analysis.htm

The construction of an antibody-drug conjugate (ADC) is the covalent coupling of a monoclonal antibody and a toxic payload drug via a linker molecule. The ultimate goal for an ADC development project is to deploy the resulted ADC into in vivo systems, both in model animals and eventually human patients, to cure cancer and other diseases utilizing its payload efficacy. However, prior to in vivo deployment, information regarding basic biochemical characteristics and in vitro efficacy must be acquired for a proper evaluation of the ADC to determine the proceedings and directions of the project. https://www.creative-biolabs.com/adc/adc-in-vitro-analysis.htm

As one major component of an antibody-drug conjugate (ADC), the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload drug can be attached to different sites on an antibody using diverse conjugation chemistry. Multiple endogenous amino acids can serve as potential conjugation sites. However, to achieve more precisely controlled site-directed conjugations and subsequently a narrower distribution of drug-to-antibody ratio (DAR), special moieties with unique conjugation chemistries are engineered into antibody sequences in our antibody design services. https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm

The antibody portion of an antibody-drug conjugate (ADC) usually occupies over 95% of its molecular weight and it serves as a cargo to deliver the remaining ~5% to the target for a lethal strike. The warhead of this precision-guided munition is comprised of a cytotoxic payload drug and a molecular linker that covalently bridges the antibody and the payload. https://www.creative-biolabs.com/adc/druglnk-custom-synthesis.htm

While conventional cancer therapies (surgery, chemo therapy, and radiation therapy) have shown some success in the battle again cancer, they are often accompanied by complex and sometimes, severe side-effects due to the lack of target specificity. To circumvent this flaw and improve the efficacy and safety of cancer treatment, targeted cancer therapies, especially antibody-drug conjugates (ADCs), have been actively exploited and they are gaining a significant amount of attention during the recent years. https://www.creative-biolabs.com/adc/adc-antibody-screening.htm

Monoclonal antibody-based immunotherapies against cancer and other infectious diseases are highly advantageous comparing to conventional therapeutic approaches due to their high specificity and affinity towards well-defined targets. Antibody-drug conjugates (ADCs) inherit such superiorities and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature. https://www.creative-biolabs.com/adc/one-stop-adc-development-service.htm

Phage Display & Antibody Library https://www.creative-biolabs.com/phage-display-service.html

The mRNA vaccine field, which represents a promising alternative to conventional vaccine approaches, is developing extremely rapidly because of their high potency, potential for rapid development and capacity for low-cost manufacture and safe administration.https://www.creative-biolabs.com/vaccine/mrna-vaccine-platform.htm

HIV is an abbreviation for human immunodeficiency virus, a lentivirus that causes acquired immunodeficiency syndrome (AIDS), which is a disease that gradually damages the body's immune system, and patients eventually die from various pathogen infections and cancer. In the absence of treatment, HIV-infected patients typically have a survival time of 9-11 years. HIV is a sexually transmitted virus that can be transmitted through contact with or transfer of the blood or body fluids such as semen of infected people. In addition, the virus can also be transmitted from infected mothers to newborns during childbirth or lactation.

Immunologic Adjuvants, which are added to vaccines, plays an important part in enhancing the immune response to the antigen. Adjuvants enhance the ability of antigens by boosting it to give a higher amount of antibody and a longer-lasting protection, thus minimizing the amount of injected foreign material.https://www.creative-biolabs.com/vaccine/category-adjuvants-5.htm

Hepatitis B virus (HBV) infection is the main cause of morbidity and mortality. Hepatitis B is an infectious liver disease that comes from hepatitis B virus infection. Acute infection may last for several weeks. If the virus stays in the body, it can cause severe chronic infections, leading to liver damage, liver cancer and death. https://www.creative-biolabs.com/vaccine/hbv-vaccines.htm

Three major components define an ADC—the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. A successful ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized.https://www.creative-biolabs.com/adc/one-stop-adc-development-service.htm

Three major components define an ADC—the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. A successful ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized.https://www.creative-biolabs.com/adc/

Monoclonal antibody-based immunotherapies against cancer and other infectious diseases are highly advantageous comparing to conventional therapeutic approaches due to their high specificity and affinity towards well-defined targets. Antibody-drug conjugates (ADCs) inherit such superiorities and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature.https://www.creative-biolabs.com/adc/one-stop-adc-development-service.htm

T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAb) are showing promising results in clinical trials.https://www.creative-biolabs.com/bsab/new-ways-of-evaluating-the-tumor-immune-microenvironment-from-bench-to-bedside.html

Key webinar highlights: Recognizing the "friend or foe" relationship between (blood) cancer and immunity Leveraging on the immunotherapies for malignant and nonmalignant (hematological) tumors Need for next-generation immune monitoring https://www.creative-biolabs.com/bsab/new-ways-of-evaluating-the-tumor-immune-microenvironment-from-bench-to-bedside.html

In this technical session, Creative Biolabs invited Dr. Bruno Paiva to give us a clearer understanding of novel immunotherapies and the combined methods to be applied in the research of tumorigenesis and drug development. https://www.creative-biolabs.com/bsab/new-ways-of-evaluating-the-tumor-immune-microenvironment-from-bench-to-bedside.html

T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAb) are showing promising results in clinical trials. To guide precision immunotherapy, other factors should also be taken into consideration, including greater availability of immune targets and compounds with different modes of action during the development of new biomarkers, and determinants of response and resistance to a specific regimen. https://www.creative-biolabs.com/bsab/new-ways-of-evaluating-the-tumor-immune-microenvironment-from-bench-to-bedside.html

Based on our proprietary technology for de novo sequencing of antibodies and our expertise in protein mass spectrometry and informatics, our standard procedures include the following steps: De Novo Antibody Sequencing WorkflowFig. 1 De Novo Antibody Sequencing Workflow. Antibody protein is initially digested into overlapping peptides using various trypsin Digestion with LC-MS/MS, then fragmentation optimization Overlapping peptides are characterized by de novo peptide sequencing Automated antibody sequence assembly using characterized peptides Data analysis is performed using state-of-the-art computational algorithms that efficiently derive the amino acid sequence of the digested peptide https://www.creative-biolabs.com/next-generation-antibody-sequencing.html

Recognizing the "friend or foe" relationship between (blood) cancer and immunity Leveraging on the immunotherapies for malignant and nonmalignant (hematological) tumors Need for next-generation immune monitoring https://www.creative-biolabs.com/bsab/new-ways-of-evaluating-the-tumor-immune-microenvironment-from-bench-to-bedside.html

To guide precision immunotherapy, other factors should also be taken into consideration, including greater availability of immune targets and compounds with different modes of action during the development of new biomarkers, and determinants of response and resistance to a specific regimen. https://www.creative-biolabs.com/bsab/new-ways-of-evaluating-the-tumor-immune-microenvironment-from-bench-to-bedside.html

Next Generation Sequencing (NGS) is a powerful platform that has enabled the sequencing of thousands to millions of DNA molecules simultaneously. Creative Biolabs has developed the SuPrecision™ platform that integrates advanced technology to provide the most in-depth cancer NGS services, which is committed to assisting in accelerating precision medical research and cancer diagnosis. This video briefly introduces NGS related information. If you need more information about NGS, please visit https://www.creative-biolabs.com/suprecision/.